Reasons reported by women for choosing the levonorgestrel intrauterine system as a contraceptive method-Reference-Cited by-同舟云学术

Reasons reported by women for choosing the levonorgestrel intrauterine system as a contraceptive method

Published:2021-12-23 Issue: Volume: Page:
ISSN:0020-7292
Container-title:International Journal of Gynecology & Obstetrics
language:en
Short-container-title:Intl J Gynecology & Obste

Author:

Laporte Montas¹,Charles Charles M.¹,Metelus Sherly¹,Peloggia Alessandra¹,Paez Gabriela de O.¹,Juliato Cassia T.¹,Bahamondes Luis¹

Affiliation:

1. Department of Obstetrics and Gynecology University of Campinas Faculty of Medical Sciences Campinas SP Brazil

Funder

World Health Organization

Publisher

Wiley

Subject

Obstetrics and Gynecology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijgo.14062

Reference23 articles.

1. World Health Organization.WHO statement on levonorgestrel‐releasing intrauterine device nomenclature. World Health Organization.2021. Available at:https://apps.who.int/iris/handle/10665/340378Accessed July 20 2021

2. Reasons for discontinuation of contraception among women with a current unintended pregnancy in 36 low and middle‐income countries;Bellizzi S;Contraception,2020

3. Effectiveness of long‐acting reversible contraception;Winner B;N Engl J Med,2012

4. Five‐year contraceptive efficacy and safety of a levonorgestrel 52‐mg intrauterine system;Teal SB;Obstet Gynecol,2019

5. Conception rates in women desiring pregnancy after levonorgestrel 52 mg intrauterine system (Liletta®) discontinuation;Carr BR;Contraception,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Women's perspectives on impact on the post menopause of use of the 52 mg levonorgestrel intrauterine device during the menopausal transition;The European Journal of Contraception & Reproductive Health Care;2023-05-30